Coloplast A/S (OTCMKTS:CLPBY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Wednesday.

According to Zacks, “Coloplast A/S develops and provides health care products and services. Its operating business segments consist of Chronic Care, Urology Care and Wound & Skin Care. The Chronic Care segment covers the sale of ostomy care products and continence care products. The Urology Care segment offers urological products, including disposable products. The Wound and Skin Care segment covers the sale of wound and skin care products. Coloplast A/S is headquartered in Humlebaek, Denmark. “

Shares of Coloplast A/S (OTCMKTS:CLPBY) traded up $0.01 during trading on Wednesday, hitting $8.45. The company had a trading volume of 57,662 shares, compared to its average volume of 160,106. Coloplast A/S has a 52 week low of $6.95 and a 52 week high of $9.01.

Coloplast A/S (OTCMKTS:CLPBY) last announced its earnings results on Thursday, February 1st. The company reported $0.07 EPS for the quarter. The business had revenue of $625.80 million for the quarter. research analysts forecast that Coloplast A/S will post 0.31 earnings per share for the current year.

WARNING: “Coloplast A/S (CLPBY) Upgraded to “Hold” by Zacks Investment Research” was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at

Coloplast A/S Company Profile

Coloplast A/S develops and markets intimate healthcare products and services worldwide. The company operates through three segments: Chronic Care, Urology Care, and Wound & Skin Care. It provides ostomy care products for intestinal dysfunction resulting from disease, accident, and congenital disorder.

Get a free copy of the Zacks research report on Coloplast A/S (CLPBY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with's FREE daily email newsletter.